Kingsley Biotech (01548) announced interim results. The loss attributable to shareholders of US$129 million narrowed 29.25% year-on-year

According to the Zhitong Finance App, Kingsley Biotech (01548) announced interim results for the six months ended June 30, 2026. The group achieved revenue of US$404 million, an increase of 27.35% over the previous year; the loss due to the company's owners was US$129 million, a year-on-year decrease of 29.25%; and a loss of 5.92 cents per share.

According to the announcement, the increase in revenue was mainly due to (i) the continued rise in demand in the AI-driven drug discovery and antibody drug discovery industry, which accelerated the growth of the “gene-to-protein” business; (ii) the strong recovery in upstream demand in the CRDMO industry, which led to an increase in project capacity utilization; and (iii) the continuous expansion of the industrial enzyme business, contributing to the steady increase in sales during the reporting period.